Shareholders who lost money in shares of LifeMD, Inc. (NASDAQ: LFMD) Should Contact Wolf Haldenstein Immediately

Lead Plaintiff Deadline is October 27, 2025

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP is notifying investors about a federal securities class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) (“LifeMD” or the “Company”).

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

LifeMD, Inc. (NASDAQ: LFMD) Securities Class Action Lawsuit

Class Period: May 7, 2025 – August 5, 2025
Lead Plaintiff Deadline: October 27, 2025
Court: United States District Court for the Eastern District of New York

Allegations

The complaint alleges that LifeMD and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that:

1. LifeMD materially overstated its competitive position.

2. The Company was reckless in raising 2025 guidance, failing to account for:

Rising customer acquisition costs in its RexMD segment, and
Costs related to acquiring customers for obesity drugs such as Wegovy and Zepbound.

3. As a result, statements about LifeMD’s business, operations, and prospects were materially false, misleading, and/or lacked a reasonable basis.

Corrective Disclosure

August 5, 2025 (after market close):
LifeMD reported Q2 2025 financial results and revised guidance:
- New revenue outlook: $250 – $255 million
- Prior guidance: $268 – $275 million
Market Reaction: On August 6, 2025, LifeMD’s stock price plummeted 44.8%.

Next Steps for Investors:

Investors who suffered losses can seek appointment as lead plaintiff prior to October 27, 2025 by contacting Wolf Haldenstein.

Why Wolf Haldenstein Adler Freeman & Herz LLP?:

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

Contact:

Phone: (800) 575-0735 or (212) 545-4774
Email: classmember@whafh.com
Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.